Efficacy of topical calcineurin inhibitors in pyoderma gangrenosum

Abdul‐fattah, Bilal; Al-Muriesh, Maher; Huang, Changzheng

doi:10.1111/dth.12697

Cited by 4 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The best evidence in the literature regarding topical therapy is for corticosteroids and tacrolimus. A case series conducted in 2011 found topical therapy to be used most often in peristomal PG, smaller lesions, and localized PG (<5% body surface area, <3 lesions, and lesions <2 cm 2 ) 5, 36, 37 . One review found that topical tacrolimus 0.3% promoted lesion resolution in mild and localized PG 37 .…”

Section: Treatmentmentioning

confidence: 99%

“…A case series conducted in 2011 found topical therapy to be used most often in peristomal PG, smaller lesions, and localized PG (<5% body surface area, <3 lesions, and lesions <2 cm 2 ) 5, 36, 37 . One review found that topical tacrolimus 0.3% promoted lesion resolution in mild and localized PG 37 . Intralesional steroids, applied to the active border of the lesion surrounding the ulcerated area, can also be used in small and localized PG 4 .…”

Section: Treatmentmentioning

confidence: 99%

“…However, improvements were slow and relapses were not uncommon. Therefore, topical therapy can be used concomitantly with systemic therapy or in patients who are resistant to or cannot tolerate steroids 37 .…”

Section: Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Recent advances in managing and understanding pyoderma gangrenosum

2019

View full text Add to dashboard Cite

Pyoderma Gangrenosum (PG) is a rare neutrophilic dermatosis with multiple different clinical presentations and associated comorbidities. PG has historically been a challenging disorder to diagnose, leading to the development of new diagnostic criteria rather than the traditional approach of a diagnosis of exclusion. The pathophysiology is thought to involve both innate and adaptive immune system dysregulation, neutrophilic abnormalities, environmental, and genetic factors. As of today, no gold standard therapy exists for the treatment of PG, and the literature is restricted to mainly case reports, case series, and 2 small randomized clinical trials. Topical, systemic, and biologic therapy, as well as adequate analgesia and proper wound care all play a role in the management of PG. Recent studies have identified additional cytokines and signalling cascades thought to be involved in the pathogenesis of PG, ultimately leading to the development of new targeted therapies. This review will focus on recent advances in the pathophysiology, clinical presentation and associated comorbidities, diagnosis, and management of PG.

show abstract

Section: Treatmentmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in managing and understanding pyoderma gangrenosum

2019

View full text Add to dashboard Cite

show abstract

“…Treatment of PG includes local treatment and systemic treatment, and local treatment includes corticosteroids and tacrolimus. [ 21 , 22 ] The most common first-line drug for systemic therapy of PG is steroids or glucocorticoids. [ 23 , 24 ] The combined use of glucocorticoids and immunosuppressive agents is mostly recommended.…”

Section: Discussionmentioning

confidence: 99%

Pyoderma gangrenosum complicated with hematological malignancies: Two case reports

Li,

Zhao,

Duan

et al. 2024

Medicine

View full text Add to dashboard Cite

Introduction: Pyoderma gangrenosum (PG) is a rare noninfectious neutrophilic skin disease. The diagnosis of PG is mainly based on clinical manifestations. Therefore, the clinical features of PG are important for confirming the diagnosis of this disease. Herein, the clinical data of 2 young males with PG complicated with hematological malignancies were reported, and the literature were reviewed. Case presentation: The first case was a 22-year-old male who was admitted due to a systemic rash, headache, and fever. Physical examination showed black scabs on the skins of the extremities, trunk, scalp, and face. Biopsy of the skin lesion showed epidermal edema, spongy formation, neutrophil infiltration, acute and chronic inflammatory cell infiltration in the dermis, showing purulent inflammation with epidermal erosion. The bone marrow biopsy showed obviously active proliferation of nucleated cells, granulocytes at various stages, abnormal morphological neutrophils, and occasionally observed young red blood cells. The diagnosis of PG and chronic myelomonocytic leukemia (CMML-0) was made. The second case was a 28-year-old male who presented a swollen, painful right calf following injury and then developed ulcers on skin and soft tissues. Bone marrow biopsy showed obviously active nucleated cell proliferation, suggesting a myeloid tumor. He was also diagnosed with PG and hematological malignancies. They both received hormone and antiinfection therapy. After treatment, their body temperature, infection, and skin lesions were improved. However, both of them were readmitted and had a poor prognosis. Conclusions: PG may be associated with hematological malignancies. For patients with typical skin lesions and obvious abnormal blood routines, it is necessary to investigate the possibility of PG with hematological malignancies.

show abstract

Enteral Feeding Devices and Ostomies

Stellar

2023

Pediatric Inflammatory Bowel Disease

View full text Add to dashboard Cite

Efficacy of topical calcineurin inhibitors in pyoderma gangrenosum

Cited by 4 publications

References 38 publications

Recent advances in managing and understanding pyoderma gangrenosum

Recent advances in managing and understanding pyoderma gangrenosum

Pyoderma gangrenosum complicated with hematological malignancies: Two case reports

Enteral Feeding Devices and Ostomies

Contact Info

Product

Resources

About